For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Patients with muscle-invasive urothelial cancer face a high risk of relapse despite radical surgery and chemotherapy. The immune checkpoint inhibitor pembrolizumab may reduce this risk. New ...

Bicycle Therapeutics (BCYC) announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously ...

(Pembrolizumab + vibostolimab) is under clinical development by Merck and currently in Phase II for Metastatic Colorectal Cancer.

TMB and various biomarkers were positively associated with improved pCR and EFS in high-risk, early-stage TNBC, regardless of ...

Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) ...